Modern therapeutic approaches can significantly correct iron-deficient co and normalize iron metabolism in women during gestation, but for this, the practitioner must make the right decision to conduct both screening studies in this group of patients and to choose the optimal personalized laboratory diagnosis in pregnant women with clinically expressed pathological changes.

The work is devoted to the necessity of conducting a screening study of thyroid function in women in the pre-gravidar period and during gestation. Pathological conditions of the thyroid gland are one of the most common diseases of the endocrine system, second only to diabetes mellitus in prevalence. At the same time, in recent years, there has been an increase in thyroid insufficiency. Clinical and subclinical hypothyroidism are the most common hormonal dysfunctions during pregnancy, which have a negative impact on the course of gestation and fetal development. At the same time, subclinical hypothyroidism is an easily treatable disease that reduces the pregnancy related morbidity of the mother and fetus. Screening only at-risk patients probably skips most cases. Therefore, guidelines should be established for universal screening of thyroid dysfunction in the pre-gravidar period and during pregnancy with their own ranges for thyroid stimulating hormone during gestation, calculated taking into account regional, ethnic and population characteristics. Levothyroxine replacement therapy in a woman with subclinical hypothyroidism in the pre-gravidar period and during pregnancy should begin immediately after the diagnosis of this condition and be adequate in terms of timing and dose.

No abstract